| Patents for A61P 13 - Drugs for disorders of the urinary system (56,135) |
|---|
| 08/29/2002 | WO2002066023A1 Use of a cyclohexenone derivatives in the manufacture of a medicament for treating diabetic complications |
| 08/29/2002 | WO2002065859A1 Emulsions and aqueous dispersions of phytosterols |
| 08/29/2002 | WO2002028858A3 Hexahydropyrazino `1'2' : 1, 6!- pyrido `3, 4-b! indole-1, 4-dione derivatives for the treatment of cardiovascular disorders and erectile disfunction |
| 08/29/2002 | WO2002020723A3 Compositions and methods for targeting peptides in humans in vivo |
| 08/29/2002 | WO2001096547A3 Human kinases |
| 08/29/2002 | WO2001085944A3 Production of adenine nucleotide translocator (ant), novel ant ligands and screening assays therefor |
| 08/29/2002 | WO2000066104A9 Ace-2 inhibiting compounds and methods of use thereof |
| 08/29/2002 | WO2000061788A3 Poly(dipeptide) as a drug carrier |
| 08/29/2002 | WO2000056866A9 Akt-3 nucleic acids, polypeptides, and uses thereof |
| 08/29/2002 | WO1999064055A9 Multivalent agonists, partial agonists, inverse agonists and antagonists of the 5ht4 receptors |
| 08/29/2002 | US20020120148 Benzocycloheptenylamino derivatives; treatment of pollakiuria or urinary incontinence |
| 08/29/2002 | US20020120147 Micronized torsemide |
| 08/29/2002 | US20020120145 Inhibiting farnesyl protein transferase. |
| 08/29/2002 | US20020120117 Polynucleotide that exhibits urothelial cell-specific transcriptional response element (TRE) activity; adenoviral vectors which replicate preferentially in urothelial cells; treating bladder cancer for example |
| 08/29/2002 | US20020119999 Imidazole dione or one, thione derivatives as antitumor and antiinflammatory agents, also treats cardiovascular disease, nephropathies and retinopathies |
| 08/29/2002 | US20020119991 Respiratory system disorders; antiallergens |
| 08/29/2002 | US20020119977 Antitumor agents; antiinflammatory agents; analgesics; antipyretic agent |
| 08/29/2002 | US20020119976 Tetracyclic derivatives, process of preparation and use |
| 08/29/2002 | US20020119964 Homoiminopiperidinyl hexanoic acid inhibitors of inducible nitric oxide synthase |
| 08/29/2002 | US20020119961 Bridged piperazine derivatives |
| 08/29/2002 | US20020119566 Methods and compositions for isolation and growth of kidney tubule stem cells, in vitro kidney tubulogenesis and ex vivo construction of renal tubules |
| 08/29/2002 | US20020119554 Arginase II |
| 08/29/2002 | US20020119202 For therapy of cancer and other angiogenic-dependent diseases |
| 08/29/2002 | US20020119164 Use of agaricus blazei murill to prevent or treat skin and other disorders |
| 08/29/2002 | US20020119148 ErbB4 antagonists |
| 08/29/2002 | US20020119144 Methods and compositions for treating platelet-related disorders using MPL pathway inhibitory agents |
| 08/29/2002 | US20020119143 Antithrombin III for disorders caused by angiogenesis |
| 08/29/2002 | US20020119104 Treatment of mucositis |
| 08/29/2002 | DE10108307A1 Substituierte Propan-1,3-diamin-Derivate Substituted propane-1,3-diamine derivatives |
| 08/29/2002 | DE10106970A1 Neues Benzoylguanidinsalz New Benzoylguanidinsalz |
| 08/29/2002 | CA2438685A1 Tryptase inhibitors |
| 08/29/2002 | CA2438682A1 Antibodies that bind both bcma and taci |
| 08/29/2002 | CA2438519A1 Emulsions and aqueous dispersions of phytosterols |
| 08/29/2002 | CA2438318A1 Novel heterocyclic amide derivatives and their use as dopamine d3 receptor ligands |
| 08/29/2002 | CA2438312A1 Anthrone derivatives and their use as jnk inhibitors |
| 08/29/2002 | CA2438241A1 Medicinal compositions comprising diclofenac and ornoprostil |
| 08/29/2002 | CA2438235A1 Neurotransmission-associated proteins |
| 08/29/2002 | CA2437529A1 Reagents and methods for identifying and modulating expression of genes regulated by cdk inhibitors |
| 08/29/2002 | CA2437242A1 Tramadol-based medicament |
| 08/29/2002 | CA2433348A1 Detection of compounds that modulate inflammatory responses |
| 08/29/2002 | CA2432208A1 Substituted heterocyclo-norbornylamine derivatives, method for producing the same, their use as medicament or diagnostic agent and medicament containing the same |
| 08/28/2002 | EP1234879A2 Human nucleic acid sequences from prostate tumour tissue |
| 08/28/2002 | EP1234037A2 DNA ENCODING A NOVEL PROST-Ets POLYPEPTIDE |
| 08/28/2002 | EP1234025A1 Human enzymes of the metalloprotease family |
| 08/28/2002 | EP1233983A2 Kunitz-type protease inhibitor polynucleotides, polypeptides, and antibodies |
| 08/28/2002 | EP1233975A1 29 human secreted proteins |
| 08/28/2002 | EP1233959A1 Heterocyclo-alkylsulfonyl pyrazole derivatives as anti-inflammatory/analgesic agents |
| 08/28/2002 | EP1233951A1 3,4-dihydro-(1h)quinazolin-2-one compounds as csbp/p38 kinase inhibitors |
| 08/28/2002 | EP1233950A1 3,4-DIHYDRO-(1H)QUINAZOLIN-2-ONE COMPOUNDS AS CSBP/P39 kINASE INHIBITORS |
| 08/28/2002 | EP1233815A1 Use of dopamine-d3 receptor agonists for the therapy of salt-dependent hypertension |
| 08/28/2002 | EP1233791A2 Methods of treating lupus based on antibody affinity and screening methods and compositions for use thereof |
| 08/28/2002 | EP1233786A2 Product comprising at least a no synthase inhibiting substance associated with at least a phospholipase a2 inhibiting substance |
| 08/28/2002 | EP1233781A1 Assays and therapies for latent viral infection |
| 08/28/2002 | EP1233777A1 Major intrinsic protein (mip)-like polynucleotides, polypeptides, and antibodies |
| 08/28/2002 | EP1233774A1 Urotensin-ii analogs |
| 08/28/2002 | EP1233773A1 Mixture of pomegranate seed oil and juice products |
| 08/28/2002 | EP1233756A1 Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| 08/28/2002 | EP0973731B1 Hydroxamic acid derivatives |
| 08/28/2002 | EP0716607B1 Biochemically balanced peritoneal dialysis solutions |
| 08/28/2002 | EP0700284B1 Controlled release oxybutynin formulations |
| 08/28/2002 | CN1366524A Sulfonamide derivative as matrix metalloproteinase inhibitor |
| 08/28/2002 | CN1366520A Medicine |
| 08/28/2002 | CN1366461A Preventive or therapeutic drugs for dermatitises containing chymase inhibitors as active ingredient |
| 08/28/2002 | CN1365826A Suppository 'Liexiantong' |
| 08/28/2002 | CN1365825A 'Yishenxingyang' instant particle |
| 08/28/2002 | CN1365798A Nano medicine 'Qinglin' and its preparing process |
| 08/28/2002 | CN1365733A Nano medicine 'Shenkangning' for treating nephrosis and its preparing process |
| 08/28/2002 | CN1365674A Nano medicine 'Fukefenqing' and its preparing process |
| 08/28/2002 | CN1365671A Nano medicine 'Fenqingwulin' and its preparing process |
| 08/28/2002 | CN1089764C Substituted heterocyclic compounds, preparation method thereof and pharmaceutical compositions containing same |
| 08/28/2002 | CN1089759C Crystal form of N-(4-trifluoromethylphenyl)-5-methylisoxazole-4-carboxamide |
| 08/28/2002 | CN1089592C Chinese medicine for treating acute and chronic nephritis |
| 08/27/2002 | US6441048 Methods of treating affective disorders using derivatives of (-)-venlafaxine |
| 08/27/2002 | US6441017 Inhibitors of prenyl-protein transferase |
| 08/27/2002 | US6441012 Chemical compounds |
| 08/27/2002 | US6441004 Monocyte chemoattractant protein-1 inhibitor compounds |
| 08/27/2002 | US6440968 Use of maduraohtalazine derivatives as inhibitors of proinflammatory cytokines |
| 08/27/2002 | US6440963 Use of selective COX-2 inhibitors for the treatment of urinary incontinence |
| 08/27/2002 | US6440962 Cardiovascular disorders, antiischemic agents |
| 08/27/2002 | US6440959 Inhibitors of cyclin-dependent kinases |
| 08/27/2002 | US6440955 Anti-inflammatory agents |
| 08/22/2002 | WO2002064755A2 Post-partum mammalian placenta, its use and placental stem cells therefrom |
| 08/22/2002 | WO2002064748A2 Multipotent adult stem cells, sources thereof, methods of obtaining and maintaining same, methods of differentiation thereof, methods of use thereof and cells derived thereof |
| 08/22/2002 | WO2002064634A2 Human monoclonal antibodies to fc alpha receptor (cd89) |
| 08/22/2002 | WO2002064627A2 Crystallization of igf-1 |
| 08/22/2002 | WO2002064616A2 Agonists and antagonists of sphingosine-1-phosphate receptors |
| 08/22/2002 | WO2002064593A1 2-alkoxyphenyl substituted imidazotriazinones |
| 08/22/2002 | WO2002064592A1 Tricyclic crf receptor antagonists |
| 08/22/2002 | WO2002064591A2 Carboline derivatives |
| 08/22/2002 | WO2002064590A2 Carboline derivatives |
| 08/22/2002 | WO2002064589A1 Laulimalide derivatives |
| 08/22/2002 | WO2002064584A1 Phthalayinone-piperidino-derivatives as pde4 inhibitors |
| 08/22/2002 | WO2002064570A1 Novel alkyl phenylimino-imidazolidine derivatives for treating urinary incontinence |
| 08/22/2002 | WO2002064565A1 Acylated 1,2,3,4-tetrahydronaphthyl amines and their use as pharmaceutical |
| 08/22/2002 | WO2002064563A1 Novel benzoylguanidine salt |
| 08/22/2002 | WO2002064546A2 Acylated 6,7,8,9-tetrahydro-5h-benzocycloheptenyl amines and their use as pharmaceutical |
| 08/22/2002 | WO2002064545A1 Acylated indanyl amines and their use as pharmaceuticals |
| 08/22/2002 | WO2002064543A2 Novel succinate salt of o-desmethyl-venlafaxine |
| 08/22/2002 | WO2002064210A2 Combination therapy comprising anti-diabetic and anticonvulsant agents |
| 08/22/2002 | WO2002064169A1 Methods of treating diseases in association with decrease in the expression of aop-1 gene or aop-1 and remedies for the diseases |